Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

Blood

Volumn 122, Issue 15, 2013, Pages 2539-2549

  Dubovsky, Jason A ^a   Beckwith, Kyle A ^a,b   Natarajan, Gayathri ^c   Woyach, Jennifer A ^a   Jaglowski, Samantha ^a   Zhong, Yiming ^a   Hessler, Joshua D ^a   Liu, Ta Ming ^a   Chang, Betty Y ^d   Larkin, Karilyn M ^a   Stefanovski, Matthew R ^a   Chappell, Danielle L ^a   Frissora, Frank W ^a   Smith, Lisa L ^a   Smucker, Kelly A ^a   Flynn, Joseph M ^a   Jones, Jeffrey A ^a   Andritsos, Leslie A ^a   Maddocks, Kami ^a   Lehman, Amy M ^c   Furman, Richard ^e   Sharman, Jeff ^f   Mishra, Anjali ^a   Caligiuri, Michael A ^a   Satoskar, Abhay R ^c   Buggy, Joseph J ^d   Muthusamy, Natarajan ^a   Johnson, Amy J ^a,c   Byrd, John C ^a,c   more..

^a Oncology and Bone Marrow Transplantation   (United States)

^b Medical Scientist Program   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d PHARMACYCLICS INC   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f Willamette Valley Cancer Institute and Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IBRUTINIB; INTERLEUKIN 2; PHOSPHOTRANSFERASE INHIBITOR; T LYMPHOCYTE RECEPTOR; ENZYME INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM TRANSPORT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; COVALENT BOND; DRUG PROTEIN BINDING; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; JURKAT CELL LINE; LISTERIOSIS; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIMARY CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SKIN LEISHMANIASIS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH2 CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; IMMUNOLOGY; LEISHMANIASIS, CUTANEOUS; LEUKEMIA; LYMPHOCYTE ACTIVATION; PRIMARY CELL CULTURE;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; HUMANS; JURKAT CELLS; LEISHMANIASIS, CUTANEOUS; LEUKEMIA; LISTERIOSIS; LYMPHOCYTE ACTIVATION; MICE; PRIMARY CELL CULTURE; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES; TH1 CELLS; TH2 CELLS;

EID: 84888216911     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-06-507947     Document Type: Article

References (46)

1. Dubovsky JA, Villagra A, Powers JJ, Wang HW, Pinilla-Ibarz J, Sotomayor EM. Circumventing immune tolerance through epigenetic modification. Curr Pharm Des. 2010;16(3):268-276.
2. Loose D, Van de Wiele C. The immune system and cancer. Cancer Biother Radiopharm. 2009; 24(3):369-376.
3. Berg LJ, Finkelstein LD, Lucas JA, Schwartzberg PL. Tec family kinases in T lymphocyte development and function. Annu Rev Immunol. 2005;23:549-600.
4. Gomez-Rodriguez J, Kraus ZJ, Schwartzberg PL. Tec family kinases Itk and Rlk/Txk in T lymphocytes: cross-regulation of cytokine production and T-cell fates. FEBS J. 2011; 278(12):1980-1989.
5. Guo W, Liu R, Ono Y, et al. Molecular characteristics of CTA056, a novel interleukin-2-inducible T-cell kinase inhibitor that selectively targets malignant T cells and modulates oncomirs. Mol Pharmacol. 2012;82(5):938-947.
6. Au-Yeung BB, Katzman SD, Fowell DJ. Cutting edge: Itk-dependent signals required for CD41 T cells to exert, but not gain, Th2 effector function. J Immunol. 2006;176(7):3895-3899.
7. Sahu N, Venegas AM, Jankovic D, et al. Selective expression rather than specific function of Txk and Itk regulate Th1 and Th2 responses. J Immunol. 2008;181(9):6125-6131.
8. Fowell DJ, Shinkai K, Liao XC, Beebe AM, Coffman RL, Littman DR, Locksley RM. Impaired NFATc translocation and failure of Th2 development in Itk-deficient CD41 T cells. Immunity. 1999;11(4):399-409.
9. Miller AT, Wilcox HM, Lai Z, Berg LJ. Signaling through Itk promotes T helper 2 differentiation via negative regulation of T-bet. Immunity. 2004; 21(1):67-80.
10. Readinger JA, Schiralli GM, Jiang JK, Thomas CJ, August A, Henderson AJ, Schwartzberg PL. Selective targeting of ITK blocks multiple steps of HIV replication. Proc Natl Acad Sci USA. 2008; 105(18):6684-6689.
11. Hussain A, Yu L, Faryal R, Mohammad DK, Mohamed AJ, Smith CI. TEC family kinases in health and disease-loss-of-function of BTK and ITK and the gain-of-function fusions ITK-SYK and BTK-SYK. FEBS J. 2011;278(12):2001-2010.
12. Marks DI, Paietta EM, Moorman AV, et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood. 2009; 114(25):5136-5145.
13. Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol. 2003;139(7): 857-866.
14. Lo HY. Itk inhibitors: a patent review. Expert Opin Ther Pat. 2010;20(4):459-469.
15. Chang BY, Huang MM, Francesco M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther. 2011; 13(4):R115.
16. Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117(23):6287-6296.
17. Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood. 2012;120(6):1175-1184.
18. Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 2010;107(29):13075-13080.
19. Alinari L, Christian B, Baiocchi RA. Novel targeted therapies for mantle cell lymphoma. Oncotarget. 2012;3(2):203-211.
20. Harrison C. Trial watch: BTK inhibitor shows positive results in B cell malignancies. Nat Rev Drug Discov. 2012;11(2):96.
21. Fowler N, Sharman JP, Smith SM, et al. The Btk inhibitor, PCI-32765, induces durable responses with minimal toxicity in patients with relapsed/refractory B-cell malignancies: results from a phase I study [abstract]. Blood. 2010;116(21): 964.
22. Byrd JC, Furman RR, Coutre S, et al. The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) promotes high response rate, durable remissions, and is tolerable in treatment naive (TN) and relapsed or refractory (RR) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) patients including patients with high-risk (HR) disease: new and updated results of 116 patients in a phase Ib/II study [abstract]. Blood. 2012;120(21):189.
23. Marcotte DJ, Liu YT, Arduini RM, et al. Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases. Protein Sci. 2010;19(3):429-439.
24. Ramsay AG, Johnson AJ, Lee AM, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest. 2008;118(7):2427-2437.
25. Porakishvili N, Roschupkina T, Kalber T, Jewell AP, Patterson K, Yong K, Lydyard PM. Expansion of CD41 T cells with a cytotoxic phenotype in patients with B-chronic lymphocytic leukaemia (B-CLL). Clin Exp Immunol. 2001;126(1):29-36.
26. Mellstedt H, Choudhury AT. T and B cells in B-chronic lymphocytic leukaemia: Faust, Mephistopheles and the pact with the Devil. Cancer Immunol Immunother. 2006;55(2): 210-220.
27. Scrivener S, Goddard RV, Kaminski ER, Prentice AG. Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma. 2003; 44(3):383-389.
28. Kay NE, Rai KR, O'Brien S. Chronic lymphocytic leukemia: current and emerging treatment approaches. Clin Adv Hematol Oncol. 2006; 4(11 Suppl 22):1-10, quiz 11-12.
29. Morrison VA. Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches. Best Pract Res Clin Haematol. 2010;23(1):145-153.
30. Vandenberghe P, Verwilghen J, Van Vaeck F, Ceuppens JL. Ligation of the CD5 or CD28 molecules on resting human T cells induces expression of the early activation antigen CD69 by a calcium- and tyrosine kinase-dependent mechanism. Immunology. 1993;78(2):210-217.
31. Son JS, Chae CS, Hwang JS, Park ZY, Im SH. Enhanced chromatin accessibility and recruitment of JUNB mediate the sustained IL-4 expression in NFAT1 deficient T helper 2 cells. PLoS ONE. 2011;6(7):e22042.
32. Forbes E, van Panhuys N, Min B, Le Gros G. Differential requirements for IL-4/STAT6 signalling in CD4 T-cell fate determination and Th2-immune effector responses. Immunol Cell Biol. 2010;88(3):240-243.
33. Liu KQ, Bunnell SC, Gurniak CB, Berg LJ. T cell receptor-initiated calcium release is uncoupled from capacitative calcium entry in Itk-deficient T cells. J Exp Med. 1998;187(10):1721-1727.
34. Schaeffer EM, Debnath J, Yap G, et al. Requirement for Tec kinases Rlk and Itk in T cell receptor signaling and immunity. Science. 1999; 284(5414):638-641.
35. Kashiwakura J, Suzuki N, Nagafuchi H, Takeno M, Takeba Y, Shimoyama Y, Sakane T. Txk, a nonreceptor tyrosine kinase of the Tec family, is expressed in T helper type 1 cells and regulates interferon gamma production in human T lymphocytes. J Exp Med. 1999;190(8): 1147-1154.
36. Pollyea DA, Smith S, Fowler N, et al. A phase I dose escalation study of the Btk inhibitor PCI-32765 in relapsed and refractory B cell non-Hodgkin lymphoma and use of a novel fluorescent probe pharmacodynamic assay [abstract]. Blood. 2009;114(22):3713.
37. Jaglowski SM, Jones JA, Flynn JM, et al. A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases [abstract]. J Clin Oncol. 2012;30(suppl). Abstract 6508.
38. Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013; 31(1):88-94.
39. Atherly LO, Brehm MA, Welsh RM, Berg LJ. Tec kinases Itk and Rlk are required for CD81 T cell responses to virus infection independent of their role in CD41 T cell help. J Immunol. 2006;176(3): 1571-1581.
40. Broussard C, Fleischacker C, Horai R, et al. Altered development of CD81 T cell lineages in mice deficient for the Tec kinases Itk and Rlk. Immunity. 2006;25(1):93-104.
41. Hoerauf A, Solbach W, Lohoff M, Röllinghoff M. The Xid defect determines an improved clinical course of murine leishmaniasis in susceptible mice. Int Immunol. 1994;6(8):1117-1124.
42. Kawakami Y, Inagaki N, Salek-Ardakani S, et al. Regulation of dendritic cell maturation and function by Bruton's tyrosine kinase via IL-10 and Stat3. Proc Natl Acad Sci USA. 2006;103(1): 153-158.
43. Gagliardi MC, Finocchi A, Orlandi P, et al. Bruton's tyrosine kinase defect in dendritic cells from X-linked agammaglobulinaemia patients does not influence their differentiation, maturation and antigen-presenting cell function. Clin Exp Immunol. 2003;133(1):115-122.
44. Görgün G, Holderried TA, Zahrieh D, Neuberg D, Gribben JG. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest. 2005;115(7): 1797-1805.
45. Horna P, Sotomayor EM. Cellular and molecular mechanisms of tumor-induced T-cell tolerance. Curr Cancer Drug Targets. 2007;7(1):41-53.
46. Fan K, Jia Y, Wang S, Li H, Wu D, Wang G, Chen JL. Role of Itk signalling in the interaction between influenza A virus and T-cells. J Gen Virol. 2012; 93(Pt 5):987-997.